Results 181 to 190 of about 12,616,892 (292)

From innovation to implementation: a case report on virtual reality for chronic pain and psychological well-being in clinical practice. [PDF]

Front Psychiatry
Rivera-Rivera N, Lopez J, Haberland N, Diaz-Guevara B.   +3 more
europepmc   +1 more source

Property Rights Entrepreneurship: The Drive for Product, Asset, and Resource Excludability

Managerial and Decision Economics, EarlyView.
ABSTRACT Property rights are foundational to market economies, and entrepreneurial activity depends heavily on the excludability afforded by property rights. Yet, the role of entrepreneurs in shaping the evolution of property rights has been so thoroughly taken for granted that it often vanishes from analyses.
Thomas J. Dean, William R. Forster, Nicholas Dew   +2 more
wiley   +1 more source

Community Dynamics in a Changing World: highlights from the 1st Puerto Rico & Caribbean Microbiome Symposium and vision for a new microbiome hub. [PDF]

Sustain Microbiol
Godoy-Vitorino F.
europepmc   +1 more source

Decoding Molecular Mechanisms of Pongamia pinnata Phytochemicals in Cancer Therapy

Medicine Advances, EarlyView.
Pongamia pinnata phytochemicals have multiple anticancer mechanisms, including antioxidant, anti‐inflammatory, anti‐metastatic, and apoptosis‐inducing activities through molecular‐level regulation. These bioactive compounds protect normal cells from oxidative stress while promoting reactive oxygen species‐mediated tumor cell death and suppressing ...
Rajib Dhar, Vetriselvan Subramaniyan
wiley   +1 more source

Characterization and quantification of microplastics in marine sediments of the Colombian Caribbean. [PDF]

PeerJ
Garzón-Rodríguez L, Tigreros-Benavides P, Ochoa-Mogollón J, Herrera-Villarraga G, Sarmiento-Sánchez C, Polania-Zenner P, Rozo-Torres G, Sanjuan-Muñoz A, Franco-Herrera A.   +8 more
europepmc   +1 more source

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques, João Pedro Stringhetta Rahal, Rafael da Cunha Gomes Ribeiro, Enzo Bogucheski Ribeiro Machado, Carlos Antonio Negrato   +4 more
wiley   +1 more source

Emergence and endemicity of arboviruses in Haiti: a review. [PDF]

IJID Reg
Louis R, Sakib SN, Fan ZH, Parker LA, Lednicky JA, Morris JG, De Rochars VMB.   +6 more
europepmc   +1 more source

Noninvasive or minimally invasive neuromodulation in animal models of acute ischemic stroke: A systematic review and meta‐analysis

Neuroprotection, EarlyView.
This systematic review and meta‐analysis assessed the cytoprotective effects of neuromodulation in preclinical models of ischemic stroke. Pooled analyses showed that neuromodulation significantly reduced infarct volume and improved neurological outcomes.
Igor Caitano Salles, Mateus Paquesse Pellegrino, Jessica Borges Kroth, Clara Lucato dos Santos, Luca Schiliro Tristao, Jullyanna Sabrysna Morais Shinosaki, Wanderley Marques Bernardo, Adriana Bastos Conforto   +7 more
wiley   +1 more source

Accelerated biological aging: the role of chronic inflammation, weathering and novel therapeutic strategies. [PDF]

Front Aging
Marin-Maldonado FM, Santiago-Rosario MJ, Fonseca-Ferrer W, Vlaar CP, Martinez-Ferrer M, Colon-Saez J, Duconge-Soler J.   +6 more
europepmc   +1 more source

SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity

Obesity, EarlyView.
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter, Julie Mount, J. Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding, Naveed Sattar, Melanie J. Davies, Kamlesh Khunti, Richard Haynes, Rachel L. Batterham   +14 more
wiley   +1 more source